Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses.

ABSTRACT:

Background

Immunotherapy has rapidly changed the treatment of early-stage non-small-cell lung cancer (NSCLC) in recent years. We aimed to summarize available evidence on the use of immunotherapy in neoadjuvant/perioperative and adjuvant settings for resectable NSCLC and explore some controversial subgroups.

Materials and methods

Systematic literature research was carried out for randomized controlled trials of neoadjuvant/perioperative chemo-immunotherapy or adjuvant immunotherapy for resectable NSCLC. Separate meta-analyses for neoadjuvant/perioperative or adjuvant immunotherapy were carried out. Subgroup analyses were also carried out to estimate the effect of immunotherapy according to tumor histology, stage, programmed death-ligand 1 (PD-L1), age, sex and smoking status.

SUBMITTER: Rossi G 

PROVIDER: S-EPMC12451348 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature